0.7955
4.60%
+0.0349
Bionano Genomics Inc stock is currently priced at $0.7955, with a 24-hour trading volume of 723.29K.
It has seen a +4.60% increased in the last 24 hours and a -23.50% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.7635 pivot point. If it approaches the $0.8135 resistance level, significant changes may occur.
Bionano Genomics Inc Stock (BNGO) Financials Data
Bionano Genomics Inc (BNGO) Revenue 2024
BNGO reported a revenue (TTM) of $33.61 million for the quarter ending September 30, 2023, a +29.82% rise year-over-year.
Bionano Genomics Inc (BNGO) Net Income 2024
BNGO net income (TTM) was -$227.28 million for the quarter ending September 30, 2023, a -94.47% decrease year-over-year.
Bionano Genomics Inc (BNGO) Cash Flow 2024
BNGO recorded a free cash flow (TTM) of -$132.43 million for the quarter ending September 30, 2023, a -11.49% decrease year-over-year.
Bionano Genomics Inc (BNGO) Earnings per Share 2024
BNGO earnings per share (TTM) was -$18.12 for the quarter ending September 30, 2023, a -26.79% decline year-over-year.
Bionano Genomics Inc Stock (BNGO) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Holmlin R. Erik | President and CEO |
May 16 '23 |
Buy |
0.64 |
15,000 |
9,639 |
806,474 |
Stewart Christopher P. | Chief Financial Officer |
May 12 '23 |
Buy |
0.67 |
50,000 |
33,415 |
281,373 |
Bionano Genomics Inc Stock (BNGO) Latest News
Bionano Announces Publication Showing that OGM Detects Over 1250 Structural Variants, including 56 Gene Fusions, in Pediatric Leukemia that were Missed by Whole Genome Sequencing
GlobeNewswire Inc.
Bionano Announces $10 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
GlobeNewswire Inc.
Bionano Announces Publication Showing that OGM Identifies Genetic Aberrations in Sarcoma Samples that May Lead to Improved Diagnosis but were Missed by Classical Cytogenetics
GlobeNewswire Inc.
Bionano Genomics (BNGO) Q4 2023 Earnings Call Transcript
The Motley Fool
Bionano to Present at TD Cowen’s 44th Annual Health Care Conference
GlobeNewswire Inc.
Bionano to Report Fourth Quarter and Year End 2023 Financial Results and Host a Conference Call and Webcast on March 5, 2024
GlobeNewswire Inc.
About Bionano Genomics Inc
Bionano Genomics, Inc. operates as a life sciences instrumentation company in the genome analysis space. The company develops and markets the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. Its Saphyr system comprises an instrument, chip consumables, reagents, and a suite of data analysis tools. The company's Bionano prep kits and labeling kits provide the critical reagents and protocols needed to extract and label high molecular weight DNA for use with the Saphyr system; and data solutions offering includes a suite of hardware and software for end-to-end experiment management, algorithms for assembling genome maps, and algorithms and databases for bioinformatics processing. It sells its instruments and consumables for research use applications primarily to laboratories associated with academic and governmental research institutions, as well as to pharmaceutical, biotechnology, and contract research companies in North America, Europe, the Middle East, India, Africa, and the Asia Pacific. Bionano Genomics, Inc. was founded in 2003 and is headquartered in San Diego, California.
Cap:
|
Volume (24h):